You are here

Recent Pfizer Press Releases

7/28/16 10:00am EDT
Pfizer and Western Oncolytics Announce Immuno-Oncology Research Collaboration to Investigate Novel Oncolytic Virus Technology

Companies plan to advance Western Oncolytics’ lead preclinical therapy into human testing

Potential combination of WO-12 with Pfizer’s oncology pipeline could enhance therapeutic benefit in patients

Pfizer Inc. (NYSE:PFE) and Western Oncolytics announced today that they have entered into a development collaboration, license and option agreement to advance Western Oncolytics’ novel oncolytic vaccinia virus, WO-12. Oncolytic viruses are viruses engineered to kill cancer cells while sparing healthy cells, which subsequently elicits anti-cancer immune responses. This collaboration in oncolytic virus development adds another novel technology platform to Pfizer’s cancer vaccine efforts and provides an additional tool to bolster its immuno-oncology portfolio.

more...
7/21/16 12:01pm EDT
Spark Therapeutics and Pfizer Announce Receipt of FDA Breakthrough Therapy Designation for SPK-9001 for the Treatment of Hemophilia B

PHILADELPHIA and NEW YORK CITY, July 21, 2016 -- Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) announced today that the U.S.

more...
7/19/16 8:00am EDT
Pfizer Receives World Health Organization Prequalification for Multi-Dose Vial Presentation of Prevenar 13®

Designation Will Enable Increased Access to Vaccine in World’s Poorest Countries

Pfizer Inc. (NYSE: PFE) announced today that the World Health Organization (WHO) has prequalified its four-dose, multi-dose vial (MDV) presentation of Prevenar 13®* (pneumococcal polysaccharide conjugate vaccine [13 – valent, adsorbed]). WHO prequalification allows for the global use of Prevenar 13® MDV by United Nations agencies and countries worldwide that require WHO prequalification.

more...
7/13/16 8:00am EDT
Pfizer Announces the Publication of Final Results from Two Pivotal Phase 3 Studies of Crisaborole Topical Ointment in Patients with Mild to Moderate Atopic Dermatitis

Phase 3 Data Published in the Journal of the American Academy of Dermatology

Pfizer Inc. (NYSE:PFE) announced today the publication of findings from two pivotal Phase 3 studies of investigational crisaborole topical ointment 2% (formerly AN2728) in the online issue of the Journal of the American Academy of Dermatology.

more...
7/12/16 4:04pm EDT
Pfizer Receives FDA Approval for Prevnar 13® in Adults Age 18 Through 49

Prevnar 13 is the only pneumococcal vaccine approved in the U.S. for patients 6 weeks through adulthood

Pfizer Inc. (NYSE:PFE) today announced that Prevnar 13® (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) received U.S. Food and Drug Administration (FDA) approval for an expanded age indication to include adults 18 through 49 years of age, in addition to the already approved indication for adults 50 years and older, for active immunization for the prevention of pneumonia and invasive disease caused by 13 Streptococcus pneumoniae (S. pneumoniae) serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F).

more...
7/8/16 8:00am EDT
Pfizer Announces Positive Top-Line Results From Phase 3 S-TRAC Trial of SUTENT® (sunitinib) as Adjuvant Therapy in Patients at High Risk of Recurrent Renal Cell Carcinoma

S-TRAC is the First RCC Trial of a Tyrosine Kinase Inhibitor to Prolong Disease-Free Survival in the Adjuvant Setting

Pfizer Inc. (NYSE:PFE) today announced that the S-TRAC clinical trial (Sunitinib Trial in Adjuvant Renal Cancer), a Phase 3 study of SUTENT versus placebo in the adjuvant setting, met its primary endpoint of improving disease-free survival (DFS) as determined by blinded independent central review in patients with renal cell carcinoma (RCC) who are at high risk for recurrence after surgery.

more...
7/6/16 8:00am EDT
Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Trial to Evaluate Avelumab as First-line Treatment for Ovarian Cancer

First Phase III trial evaluating the addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer

New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women

Merck KGaA, Darmstadt, Germany, and Pfizer (NYSE: PFE) today announced the initiation of a Phase III study, JAVELIN Ovarian 100, to evaluate the efficacy and safety of avelumab* in combination with, and/or as follow-on (maintenance) treatment to, platinum-based chemotherapy in patients with locally advanced or metastatic disease (Stage III or Stage IV) with previously untreated epithelial ovarian cancer. JAVELIN Ovarian 100 is the first Phase III study evaluating the addition of an immune checkpoint inhibitor to standard-of-care in first-line treatment for this aggressive disease.

more...
6/28/16 8:30am EDT
Two Additional Phase 3 Lipid-Lowering Studies of Bococizumab Deliver Positive Topline Results

SPIRE-HR and SPIRE-FH trials met primary endpoints in patients at high and very high risk for cardiovascular events

Pfizer Inc.

more...
6/27/16 11:30pm EDT
Pfizer Advances Biosimilars Leadership with Investment in a New World-Class Global Biotechnology Center in China

Pfizer’s state-of-the-art facility will foster the continued development of the biotechnology industry in China, further supporting National healthcare reforms

Pfizer Inc. today announced that it will invest approximately USD$350 million in the development of a state-of-the-art Global Biotechnology Center at a ground-breaking ceremony in the Hangzhou Economic Development Area (HEDA) in China.

more...
6/24/16 9:00am EDT
Pfizer Completes Acquisition of Anacor

Tender offer for all of the outstanding shares of Anacor common stock expired as scheduled immediately after 11:59 p.m., New York City time, on June 23, 2016

Pfizer and Anacor begin joint operations on June 24, 2016

Pfizer Inc. (NYSE:PFE) today announced that it has completed its acquisition of Anacor Pharmaceuticals, Inc. Under the terms of the transaction, each outstanding share of Anacor common stock has been converted into the right to receive $99.25 net in cash (without interest but subject to required withholding of taxes).

more...
6/23/16 4:00pm EDT
Pfizer Declares 30-Cent Third-Quarter 2016 Dividend

The board of directors of Pfizer Inc. today declared a 30-cent third-quarter 2016 dividend on the company’s common stock, payable September 1, 2016, to shareholders of record at the close of business on August 5, 2016. The third-quarter 2016 cash dividend will be the 311th consecutive quarterly dividend paid by Pfizer.

Pfizer Inc.

more...
6/21/16 10:00am EDT
Pfizer Invites Public To View And Listen To Webcast Of August 2 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 2, 2016. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2016 Performance Report, to be issued that morning.

more...
6/16/16 9:00am EDT
Help Pfizer Change The Future Of Healthy Aging

First-of-its-kind Partnership with Indiegogo Will Help Develop the Next Big Idea in Healthy Aging

Pfizer Inc. is challenging people across the United States (U.S.) to develop the next big idea in healthy aging through a unique partnership with crowdfunding platform Indiegogo.

more...
6/16/16 8:30am EDT
Pfizer Breaks Ground On New Biologics Clinical Manufacturing Facility In Andover, Massachusetts

Pfizer Inc. today broke ground for its new biologics clinical manufacturing facility in Andover, Massachusetts. Expanding the company’s presence in the state, Pfizer will invest more than $200 million in development of the 175,000 sq. ft. state-of-the-art facility that will enable the production of high-quality, complex biologics and vaccines.

more...
6/12/16 5:15am EDT
Pfizer Announces Final Results from Inotuzumab Ozogamicin Pivotal Phase 3 Study in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

  • Results of INO-VATE ALL Trial Published in The New England Journal of Medicine
  • Overall Survival Data Also Presented as a Late-Breaking Oral Presentation at EHA 2016

Pfizer Inc.

more...
6/11/16 11:00am EDT
Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes

  • Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction 

Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints. The study results showed statistically significant reductions in A1C (a measure of average blood glucose) for both ertugliflozin doses tested (5 mg and 15 mg daily).

more...
6/9/16 7:30am EDT
Pro Golfer Jim Furyk Teams Up With Pfizer To Raise Awareness For Pneumococcal Pneumonia And The Importance Of Older Adult Vaccination

Furyk Takes Time to Coach His Coach, His Father, and Other Adults 65 and Older About the Risk for Potentially Serious Infectious Diseases, Like Pneumococcal Pneumonia

This Father’s Day, Jim Furyk will be thinking about more than just strategizing for the next Major as he joins Pfizer to encourage adults 65 and older to take responsibility for their health. On Father’s Day 2003, Furyk won a Major with his coach and father, Mike, by his side.1 This year, Jim will be one of 156 golfers to gather in Oakmont, PA, to play in one of professional golf’s major championship tournaments.

more...
6/8/16 7:15pm EDT
Pfizer Announces FDA Advisory Committees’ Recommend ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) Extended-Release Capsules for Approval

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee voted (9 to 6) in favor of approval of ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules for its proposed indication, “management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.”

more...
6/8/16 7:01am EDT
Pfizer Research Advances Body Of Evidence For Tofacitinib Citrate (XELJANZ®) Providing Clinicians With Additional Information For The Treatment Of Moderate to Severe RA

More Than 20 Abstracts will be Featured at the European League Against Rheumatism Annual Congress (EULAR 2016)
 

Pfizer Inc. (NYSE:PFE) announced today that 23 abstracts1, including research and analyses for tofacitinib citrate (XELJANZ®), will be featured at the upcoming European League Against Rheumatism (EULAR) Congress (June 8-11, London). The research being shared at the meeting provides new and additional information on the efficacy and safety profile of tofacitinib citrate, including its use as a single agent without methotrexate.

more...
6/7/16 10:00am EDT
A Mother’s Mission to Help Prevent Another Life Lost to MenB

The Kimberly Coffey Foundation and Pfizer Partner on National Meningococcal Disease Awareness Survey to Highlight Gap in MenB Knowledge Among Parents

One moment Patti Wukovits was preparing for her daughter’s high school graduation, and the next moment she was watching her fight for her life for 9 days in the intensive care unit. In 2012, Patti lost her 17-year-old daughter, Kimberly Coffey, to group B meningococcal disease, also known as MenB, just days before Kim’s senior prom and high school graduation.

more...

Pages